Hyporesponsiveness to recombinant human erythropoietin

Nephrology Dialysis Transplantation

Volumn 16, Issue SUPPL. 7, 2001, Pages 25-28

  Drüeke, Tilman ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Anaemia; Dialysis; Epoetin; Hypoparathyroidism; Hyporesponsiveness; Iron deficiency

Indexed keywords

ALUMINUM; ASCORBIC ACID; CALCIUM CARBONATE; CYANOCOBALAMIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; IRON; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; ASCORBIC ACID DEFICIENCY; CASE REPORT; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; CYTOKINE RELEASE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RESPONSE; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FEMALE; FOLIC ACID DEFICIENCY; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; INFECTION; INFLAMMATION; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON METABOLISM; KIDNEY FAILURE; PRIORITY JOURNAL;

EID: 0035168242     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.suppl_7.25     Document Type: Article

References (19)

1. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure
2. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure
3. European Best Practice Guidelines: Inadequate response to epoetin
4. Effect of aluminium overload on the bone marrow response to recombinant human erythropoetin
5. A randomised controlled study of iron supplementation in patients treated with erythropoietin
6. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron administration
7. Meeting the challenges of a new millennium: Optimizing the use of recombinant human erythropoietin
8. The role of inflammation in the anaemia of end-stage renal disease
9. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
10. Predictors of erythropoietin responsiveness in chronic hemodialysis patients
11. Cellular mechanism of resistance to erythropoietin
12. Hematocrit and erythropoietin dose are associated with dose of dialysis among adult hemodialysis patients: Results from the 1998 ESRD Core Indicators Project
13. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients
14. Pathogenesis of secondary hyperparathyroidism of chronic renal failure
15. Primary hyperparathyroidism and anemia
16. Anemia in primary hyperparathyroidism
17. R-HuEpo hyporesponsiveness-who and why
18. Parathyroidectomy and response to erythropoietin therapy in anaemic patients with chronic renal failure
19. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration